Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01111838 · ClinicalTrials.gov registry record · Phase 2

Clinical and Translational Study of STA-9090

A Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target
1
Study location

NCT01111838: Completed Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT01111838 is a Phase 2 study of Colon Cancer and Rectal Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01111838, a Phase 2 study of Colon Cancer and Rectal Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out what effects, good and/or bad STA-9090 has on colorectal cancer. This is a phase II trial which tests both how well the drug works in fighting your cancer as well as any possible side effects it will have on the patient. Cancer is a disease of uncontrolled growth. This growth is controlled in part by a series of proteins that are part of a growth pathway. Some of these proteins are destroyed by a protein called HSP90 and STA-9090 is a test drug which blocks one of the proteins that helps cancer grow. This study will also look at molecular markers that may affect how the cancer grows, and how it responds to treatment.

Primary Outcome

Patients with measurable disease will be evaluated using RECIST criteria for determination of response.

Interventions

  • DRUG STA-9090

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-04
Est. Completion 2012-07
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT01111838 record still lists

NCT01111838 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which STA-9090 is the first listed.

NCT01111838 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01111838 about?

NCT01111838 is a clinical study titled "Clinical and Translational Study of STA-9090". The purpose of this study is to find out what effects, good and/or bad STA-9090 has on colorectal cancer. This is a phase II trial which tests both how well the drug works in fighting your cancer as well as any possible side effects it will have on the patient. Cancer is a disease of uncontrolled g...

What is the current status of trial NCT01111838?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2010-04. Estimated completion is 2012-07.

What conditions does trial NCT01111838 study?

This clinical trial studies the following conditions: Colon Cancer, Rectal Cancer.

What interventions are being tested in trial NCT01111838?

The interventions under investigation include: STA-9090 (DRUG).

Who is sponsoring clinical trial NCT01111838?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01111838 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colon Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01111838's enrollment target sits among peer trials

20 87th of 97 higher than 8 of 97 other Colon Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01111838, the US trial registry maintained by the National Library of Medicine. NCT01111838 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.